Axcella Health (AXLA) Tops Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Axcella Health (AXLA) Tops Q2 EPS by 1c

Axcella Reports Second Quarter Financial Results and Provides Business Update

July 29, 2021 7:28 AM EDT

Initiated EMMPOWER Phase 2 clinical trial of AXA1665 for the reduction in risk of recurrent OHE Initiated EMMPACT Phase 2b clinical trial of AXA1125 for the treatment of NASH Presented data at key medical congresses Enhanced management team with the addition of Chief People Officer Company to host conference call at 8:30 a.m. ET today

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic... More